You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lenvatinib Mesilate

Showing 1 - 25 of 391
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Efficacy of Lenvatinib in Differentiated Thyroid Cancer

Recruiting
  • Differentiated Thyroid Cancer
  • Gender
  • Rome, Italy
    Regina Elena National Cancer Institute
Mar 16, 2023

Overall Survival in Unresectable Hepatocellular Carcinoma

Completed
  • Carcinoma, Hepatocellular
  • +3 more
  • Osaka, Japan
  • +1 more
Mar 7, 2022

Hepatic Encephalopathy in Unresectable Hepatocellular Carcinoma

Completed
  • Carcinoma, Hepatocellular
  • Osaka, Japan
  • +1 more
Jan 20, 2021

Sepsis, Sepsis-induced Coagulopathy, Nafamostat Mesilate Trial (Nafamostat mesilate, 5% glucose)

Not yet recruiting
  • Sepsis
  • +2 more
  • Nafamostat mesilate
  • 5% glucose
  • (no location specified)
Oct 5, 2023

NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

Recruiting
  • NSCLC
  • Furmonertinib 160mg
  • Furmonertinib 240mg
  • Shanghai, China
    Shanghai Chest hospital
Jan 16, 2023

Sepsis Trial in Beijing (16mg,KB, Placebos)

Recruiting
  • Sepsis
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 18, 2022

Carcinoma, Renal Cell Trial in China (Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab)

Recruiting
  • Carcinoma, Renal Cell
  • Pembrolizumab
  • +3 more
  • Beijing, Beijing, China
  • +16 more
Jun 2, 2023

Hepatocellular Carcinoma Trial in Taoyuan (ADI-PEG20)

Recruiting
  • Hepatocellular Carcinoma
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou branch
Sep 6, 2023

Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)

Not yet recruiting
  • Liver Cancer
  • +2 more
  • Lenvatinib Oral Product Plus VIC1911
  • Shanghai, China
    Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine,
Jan 30, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Metastatic Non Small Cell Lung Cancer, KRAS G12C Trial in Worldwide (Sotorasib, Lenvatinib)

Not yet recruiting
  • Metastatic Non Small Cell Lung Cancer
  • KRAS G12C
  • Innsbruck, Austria
  • +14 more
Sep 28, 2023

Carcinoma, Renal Cell Trial in Worldwide (Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab)

Recruiting
  • Carcinoma, Renal Cell
  • Pembrolizumab
  • +3 more
  • Birmingham, Alabama
  • +229 more
Aug 11, 2022

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Prostate Cancer Metastatic, Neuroendocrine Tumors Trial in Atlanta, Ann Arbor (Pembrolizumab, Lenvatinib)

Recruiting
  • Prostate Cancer Metastatic
  • Neuroendocrine Tumors
  • Duarte, California
  • +2 more
Jan 18, 2023

Lenvatinib in Combination With Pembrolizumab in Korean Patients

Recruiting
  • Endometrial Neoplasms
  • +2 more
  • Non-interventional
  • Ilsan, Gyeongji-do, Korea, Republic of
  • +14 more
Nov 21, 2022

Hepatocellular Carcinoma Trial in China, United States (CS1003+Lenvatinib, CS1003 Placebo+Lenvatinib)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Nofazinlimab (CS1003)+Lenvatinib
  • Nofazinlimab (CS1003) Placebo+Lenvatinib
  • Coronado, California
  • +5 more
Nov 7, 2022

Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma Trial in Worldwide (Eribulin

Completed
Has Results
  • Refractory or Recurrent Solid Tumors
  • +3 more
  • Eribulin mesilate
  • Irinotecan hydrochloride
  • Marseille, Bouches-du-Rhône, France
  • +38 more
Jun 20, 2022

Advanced Endometrial Cancer Trial in China (Envafolimab+Lenvatinib, Envafolimab)

Recruiting
  • Advanced Endometrial Cancer
  • Beijing, Beijing, China
  • +18 more
Jan 2, 2023

Solid Tumors Trial in Chongqing (F520, Lenvatinib)

Recruiting
  • Solid Tumors
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Feb 13, 2023

Advanced HCC Trial (Lenalidomide)

Not yet recruiting
  • Advanced HCC
  • (no location specified)
Apr 16, 2023

Endometrial Tumors Trial in Worldwide (Pembrolizumab, Lenvatinib, Paclitaxel)

Active, not recruiting
Has Results
  • Endometrial Neoplasms
  • Phoenix, Arizona
  • +168 more
Nov 23, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Jul 12, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023